Will GLP-1 Analogues and SGLT-2 Inhibitors Become New Game Changers for Diabetic Retinopathy?
Diabetic retinopathy (DR) is the most frequent microvascular complication of diabetes mellitus (DM), estimated to affect approximately one-third of the diabetic population, and the most common cause of preventable vision loss. The available treatment options focus on the late stages of this complica...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-10-01
|
| Series: | Journal of Clinical Medicine |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2077-0383/11/20/6183 |
| _version_ | 1797440754432344064 |
|---|---|
| author | Katarzyna Wołos-Kłosowicz Wojciech Matuszewski Joanna Rutkowska Katarzyna Krankowska Elżbieta Bandurska-Stankiewicz |
| author_facet | Katarzyna Wołos-Kłosowicz Wojciech Matuszewski Joanna Rutkowska Katarzyna Krankowska Elżbieta Bandurska-Stankiewicz |
| author_sort | Katarzyna Wołos-Kłosowicz |
| collection | DOAJ |
| description | Diabetic retinopathy (DR) is the most frequent microvascular complication of diabetes mellitus (DM), estimated to affect approximately one-third of the diabetic population, and the most common cause of preventable vision loss. The available treatment options focus on the late stages of this complication, while in the early stages there is no dedicated treatment besides optimizing blood pressure, lipid and glycemic control; DR is still lacking effective preventive methods. glucagon-like peptide 1 receptor agonists (GLP-1 Ras) and sodium-glucose cotransporter 2 (SGLT-2) inhibitors have a proven effect in reducing risk factors of DR and numerous experimental and animal studies have strongly established its retinoprotective potential. Both drug groups have the evident potential to become a new therapeutic option for the prevention and treatment of diabetic retinopathy and there is an urgent need for further comprehensive clinical trials to verify whether these findings are translatable to humans. |
| first_indexed | 2024-03-09T12:13:53Z |
| format | Article |
| id | doaj.art-78a92a55939448898f61bff02647f5ad |
| institution | Directory Open Access Journal |
| issn | 2077-0383 |
| language | English |
| last_indexed | 2024-03-09T12:13:53Z |
| publishDate | 2022-10-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Journal of Clinical Medicine |
| spelling | doaj.art-78a92a55939448898f61bff02647f5ad2023-11-30T22:49:33ZengMDPI AGJournal of Clinical Medicine2077-03832022-10-011120618310.3390/jcm11206183Will GLP-1 Analogues and SGLT-2 Inhibitors Become New Game Changers for Diabetic Retinopathy?Katarzyna Wołos-Kłosowicz0Wojciech Matuszewski1Joanna Rutkowska2Katarzyna Krankowska3Elżbieta Bandurska-Stankiewicz4Clinic of Endocrinology, Diabetology and Internal Medicine, School of Medicine, Collegium Medicum, University of Warmia and Mazury in Olsztyn, 10-900 Olsztyn, PolandClinic of Endocrinology, Diabetology and Internal Medicine, School of Medicine, Collegium Medicum, University of Warmia and Mazury in Olsztyn, 10-900 Olsztyn, PolandClinic of Endocrinology, Diabetology and Internal Medicine, School of Medicine, Collegium Medicum, University of Warmia and Mazury in Olsztyn, 10-900 Olsztyn, PolandClinic of Endocrinology, Diabetology and Internal Medicine, School of Medicine, Collegium Medicum, University of Warmia and Mazury in Olsztyn, 10-900 Olsztyn, PolandClinic of Endocrinology, Diabetology and Internal Medicine, School of Medicine, Collegium Medicum, University of Warmia and Mazury in Olsztyn, 10-900 Olsztyn, PolandDiabetic retinopathy (DR) is the most frequent microvascular complication of diabetes mellitus (DM), estimated to affect approximately one-third of the diabetic population, and the most common cause of preventable vision loss. The available treatment options focus on the late stages of this complication, while in the early stages there is no dedicated treatment besides optimizing blood pressure, lipid and glycemic control; DR is still lacking effective preventive methods. glucagon-like peptide 1 receptor agonists (GLP-1 Ras) and sodium-glucose cotransporter 2 (SGLT-2) inhibitors have a proven effect in reducing risk factors of DR and numerous experimental and animal studies have strongly established its retinoprotective potential. Both drug groups have the evident potential to become a new therapeutic option for the prevention and treatment of diabetic retinopathy and there is an urgent need for further comprehensive clinical trials to verify whether these findings are translatable to humans.https://www.mdpi.com/2077-0383/11/20/6183diabetic retinopathyglucagon-like peptide 1 receptor agonistsGLP-1 Rassodium-glucose cotransporter 2 inhibitorsSGLT-2 inhibitors |
| spellingShingle | Katarzyna Wołos-Kłosowicz Wojciech Matuszewski Joanna Rutkowska Katarzyna Krankowska Elżbieta Bandurska-Stankiewicz Will GLP-1 Analogues and SGLT-2 Inhibitors Become New Game Changers for Diabetic Retinopathy? Journal of Clinical Medicine diabetic retinopathy glucagon-like peptide 1 receptor agonists GLP-1 Ras sodium-glucose cotransporter 2 inhibitors SGLT-2 inhibitors |
| title | Will GLP-1 Analogues and SGLT-2 Inhibitors Become New Game Changers for Diabetic Retinopathy? |
| title_full | Will GLP-1 Analogues and SGLT-2 Inhibitors Become New Game Changers for Diabetic Retinopathy? |
| title_fullStr | Will GLP-1 Analogues and SGLT-2 Inhibitors Become New Game Changers for Diabetic Retinopathy? |
| title_full_unstemmed | Will GLP-1 Analogues and SGLT-2 Inhibitors Become New Game Changers for Diabetic Retinopathy? |
| title_short | Will GLP-1 Analogues and SGLT-2 Inhibitors Become New Game Changers for Diabetic Retinopathy? |
| title_sort | will glp 1 analogues and sglt 2 inhibitors become new game changers for diabetic retinopathy |
| topic | diabetic retinopathy glucagon-like peptide 1 receptor agonists GLP-1 Ras sodium-glucose cotransporter 2 inhibitors SGLT-2 inhibitors |
| url | https://www.mdpi.com/2077-0383/11/20/6183 |
| work_keys_str_mv | AT katarzynawołoskłosowicz willglp1analoguesandsglt2inhibitorsbecomenewgamechangersfordiabeticretinopathy AT wojciechmatuszewski willglp1analoguesandsglt2inhibitorsbecomenewgamechangersfordiabeticretinopathy AT joannarutkowska willglp1analoguesandsglt2inhibitorsbecomenewgamechangersfordiabeticretinopathy AT katarzynakrankowska willglp1analoguesandsglt2inhibitorsbecomenewgamechangersfordiabeticretinopathy AT elzbietabandurskastankiewicz willglp1analoguesandsglt2inhibitorsbecomenewgamechangersfordiabeticretinopathy |